For people with bronchiectasis, the symptoms and exacerbations of the disease can have a debilitating impact on their quality of life. This chronic, progressive respiratory disorder can cause persistent coughing and repeated infections. Bronchiectasis is growing in prevalence and there are limited treatment options available. But there is hope – our Clinical Trials Unit is at the forefront of innovative new treatments…
We are excited by the positive top-line results recently announced from one of our clinical trials into a new treatment for bronchiectasis. Patients in the WILLOW Trial have shown significant reductions in both the duration and severity of pulmonary exacerbations (increases in severity of disease symptoms).
“Right now, there are no approved pharmaceutical therapies out there for patients who are struggling to manage this disease,” Principal Investigator and GMRF Respiratory Research Unit Head Associate Professor Rachel Thomson says.
“There is an urgent need for new treatments and these trial results represent a significant step forward in addressing this problem. By helping patients better manage repeated infections and inflammation, you can greatly reduce the suffering associated with this disease, enabling people to get on with their lives.”
While more research and clinical trials are needed, the top-line results of this study highlight the tremendous value of clinical trials in providing patients with access to more effective, simpler treatments.
Read more on the top-line results here: http://bit.ly/2v6SKvC.